Amneal Pharmaceuticals' Q3 revenue beats estimates, raises guidance for adjusted EBITDA

Amneal Pharmaceuticals

30/10/2025 10:19

Overview

Amneal Q3 2025 revenue grows 12% yr/yr to $785 mln, beating analyst expectations

Adjusted diluted EPS for Q3 2025 rises to $0.17, exceeding analyst estimates

Company raises full-year 2025 adjusted EBITDA and operating cash flow guidance

Outlook

Amneal maintains 2025 revenue guidance at $3.0 bln to $3.1 bln

Company raises 2025 adjusted EBITDA guidance to $675 mln - $685 mln

Amneal increases 2025 adjusted diluted EPS guidance to $0.75 - $0.80

Result Drivers

SPECIALTY SEGMENT GROWTH - Driven by key branded products including CREXONT® and UNITHROID®

AFFORDABLE MEDICINES GROWTH - Strong performance from complex product portfolio and new launches

AVKARE SEGMENT GROWTH - Growth in government label sales channel

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$784.51 mln
$768.10 mln (4 Analysts)
Q3 Net Income
$18.13 mln
Q3 Gross Profit
$273.97 mln
Q3 Operating Income
$70.34 mln
Q3 Pretax Profit
-$5.22 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Amneal Pharmaceuticals Inc is $12.00, about 13.1% above its October 29 closing price of $10.43

The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release: ID:nGNX163P0p

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)